 Connection
Shelley Miyamoto to Immunosuppressive Agents
This is a "connection" page, showing publications Shelley Miyamoto has written about Immunosuppressive Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.267 |
|
|
|
-
Heble A, Everitt MD, Gralla J, Miyamoto SD, Lahart M, Eshelman J. Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures. Pediatr Transplant. 2018 02; 22(1).
Score: 0.111
-
Auerbach SR, Gralla J, Campbell DN, Miyamoto SD, Pietra BA. Steroid avoidance in pediatric heart transplantation results in excellent graft survival. Transplantation. 2014 Feb 27; 97(4):474-80.
Score: 0.086
-
Almond CS, Sleeper LA, Rossano JW, Bock MJ, Pahl E, Auerbach S, Lal A, Hollander SA, Miyamoto SD, Castleberry C, Lee J, Barkoff LM, Gonzales S, Klein G, Daly KP. The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score. Am Heart J. 2023 06; 260:100-112.
Score: 0.040
-
Grady KL, Andrei AC, Shankel T, Chinnock R, Miyamoto SD, Ambardekar AV, Anderson A, Addonizio L, Latif F, Lefkowitz D, Goldberg LR, Hollander SA, Pham M, Van't Hof K, Weissberg-Benchell J, Yancy C, Liu M, Melody N, Pahl E. Pediatric Heart Transplantation: Transitioning to Adult Care (TRANSIT): Feasibility of a Pilot Randomized Controlled Trial. J Card Fail. 2019 Dec; 25(12):948-958.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|